Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-87704916
- Development stage
- Phase 1
- Lead developer
- Johnson & Johnson
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral
01
Overview
JNJ-87704916 is a recombinant oncolytic herpes simplex virus type 1 (HSV-1) developed as an investigational therapy for cancer. It is designed to preferentially infect and replicate within tumor cells, leading to viral-mediated tumor cell lysis and antineoplastic effects. The drug is administered via intratumoral injection and is currently being evaluated as both monotherapy and in combination with other agents, such as cetrelimab, for the treatment of advanced solid tumors including metastatic solid tumors and relapsed or refractory metastatic non-small cell lung cancer. The developer of this agent is Johnson & Johnson.
- Other names
- oncolytic HSV-1 JNJ-87704916
02
Targets
HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))TMEFF2NECTIN1 (Poliovirus receptor-related 1)
Beyond the preview
Go deeper on JNJ-87704916.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-87704916.